MBIA, L-1 Identity: Volume Movers

NEW YORK (TheStreet) -- MBIA (MBI) was one of several stocks trading near $5 poised to move on above-average volume Tuesday after a mutual fund disclosed a large stake in the bond insurer.

MBIA shares rose after Fairholme Capital Management, a mutual fund headed by Bruce Berkowitz, disclosed in a regulatory filing late Monday that it owns more than 22.73 million shares of the bond insurer, or 11.1% of MBIA's outstanding stock.

Shares of MBIA jumped by 35 cents, or 5.4%, to $6.78 in the premarket session. The three-month average daily volume for MBIA is 9.91 million, according to Yahoo! Finance.

Fellow bond insurer Ambac Financial (ABK), which received a delisting warning from the New York Stock Exchange last week, was up 7.3% to 70 cents in Tuesday's premarket session.

Elsewhere, L-1 Identity Solutions (ID) slumped by 43 cents, or 5.7%, to $7.08 in Monday's late trading session after the personal identity technology company lowered its second-quarter revenue guidance to a range of $162 million to $167 million, below the Thomson Reuters average estimate for revenue of $180 million.

L-1 Identity Solutions said it will report second-quarter results on July 28, and it will also update investors on its plans to sell the company. The three-month average daily volume for L-1 Identity is 748,000.

Shares of National Bank of Greece (NBG) climbed by 8 cents, or 3.3%, to $2.54 in Tuesday's premarket session on a report that Greece, which continues to struggle with its debt load, raised roughly $2 billion in a bond auction. The three-month average daily volume for National Bank of Greece is 10.54 million.

In addition, Threshold Pharmaceuticals (THLD) jumped by 8 cents, or 7.9%, to $1.09 in the premarket session after the company announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, which selectively targets pancreatic cancer cells. The company said all combination therapy treatment groups (TH-302 plus sunitinib or sorafenib) "exhibited superior efficacy compared to the corresponding monotherapy groups."

Additionally, Threshold Pharmaceuticals said a separate presentation supports the hypothesis that TH-302 and gemcitabine "work in a complementary manner by targeting two distinct tumor compartments.". The 50-day average daily volume for Threshold is 50,000, according to the Nasdaq.

-- Written by Robert Holmes in Boston.

Check out all of Tuesday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.